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Ethical Implications of Treatment for Gender Dysphoria in Youth
Kelsey Hayes
College of Our Lady of the Elms
ABSTRACT
This manuscript explores ethical implications of treatment for youth with diagnosed
gender dysphoria. The ethical condiderations outlined and analyzed in this essay
involve illuminating an understanding of whether the administration of pubertal
suppression with GnRH agonists, and cross-sex hormones to children with gender
dysphoria is morally justified as treatment to manage their psychological distress, or if
safer more understood alternatives exist. This essay emphasizes that as health care
professionals, we must ensure youth with genger dysphoria receive adequate medical
treatment and care. This essay concludes through extensive literature review, that the
use of inconclusive and underresearched methods to manage gender dysphoria cannot
be ethically justified and therefore should be re-evaluated.
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1. Introduction
In the past few decades, individuals who self-identify as transgender and many
whom may meet the DSM-5 diagnostic criteria for Gender Dysphoria, seem to have
revealed their desired identities online and in their physical lives. Online, this is reflected
through thousands, of websites, blogs, and discussion groups which provide information
about what it means to be transgender, how to access health care, and, social support
outlets [24]. In recent years, the number of specialised gender identity clinics have
increased rapidly, with new programs established in Australia, Western Europe, North
America and other areas, reporting a sharp increase in referral rates [24]. With the rise
of these developments, it is appropriate to provide insight into the ethical implications
which present when support for these individuals approaches underdeveloped medical
treatment.
Gender dysphoria (GD) is a condition that is marked by psychological suffering
due to incongruence between an individual’s experienced or expressed gender and
their biologically assigned sex [4].The manifestation of GD can be observed during
childhood and adolescent development both in the prepubertal and postpubertal stages.
In gender dysphoric children and adolescents, puberty initiates the development of
undesirable sexual characteristics causing acute suffering due discordance with their
biologically assigned sex [4]. Although the prevalence of gender dysphoria, as it is
indicated in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), remains
a relatively uncommon diagnosis, there is sufficient evidence that its prevalence has
increased recent decades [24]. In recent years, there has been an increase in referral
rates to specialised gender identity clinics, underscoring the rising prevalence of this
diagnosis. Recent studies suggest that the prevalence of a self-reported transgender

identity in children, adolescents and adults ranges from 0.5 to 1.3%, markedly higher
than prevalence rates based on clinic-referred samples of adults only; emphasizing the
increasing prevalence among youth populations [24]. Pubertal suppression with
gonadotropin releasing hormone analogs (GnRHa) have been proposed for individuals
with GD in the pediatric and adolescent population as a treatment for postponing the
pubertal development with the goal to attenuate psychological suffering. Pubertal
suppression with GnRH agonists combined with cross-sex hormones in children and
adolescents are being considered, and performed in order to decrease the adversities
of gender dysphoria in this population.
Children with gender dysphoria experience distress over their gender
incongruence and, if they successfully undergo the pubertal development of what they
attribute as their incorrect gender, their psychological well-being could deteriorate
significantly. Studied children and adolescents in this population develop depression
and suicidal ideation, and further may experience alienation, and harassment in their
social environments for their inability to be socially accepted in cross-gender sports,
restrooms or similar gender specific experiences [5]. Such circumstances may lead to
the development of increased psychiatric morbidity. Due to these risks, many medical
professionals, family members of gender dysphoric children and society at large feel
medical and psychological intervention is appropriate at addressing these concerns.
Gender, is a term coined which refers to the psychological and cultural
characteristics associated with biological sex. The term gender is a psychological and
sociological concept. Gender dysphoria in pediatric and adolescent cases, may lead to
the formation of a transgendered individual. Transgender refers to an individual with a
gender identity that does not conform to expectations based on the sex they were
assigned at birth. In simplest terms, it is a discordance between gender, identity and sex
[1]. Identical twin studies demonstrate these psychological and sociological factors
which predominate in the development of gender dysphoria [18]. Family and peer
relationships, one’s ecological influences and their experiences impact an individual’s
emotional, social, and psychological development [18]. Studies suggest that social
reinforcement, parental psychopathology, family dynamics, and social influence
facilitated by various forms of media, all contribute to the development of GD in children
[5].
1.1 Treatment directions for gender dysphoric youth
In the past, medicine utilized psychological interventions focusing on aligning the
mind with the body, and addressing underlying ideologies or potential misconceptions
treating GD as a psychological condition, not a physical one [1]. In recent years, the
paradigm has shifted, ideology now stating that the mind is correct, and the body is
afflicted, and new interventions focus on aligning the body to what the mind believes by
implementing pubertal suppression with GnRH agonists, cross-sex hormones, and sex
reassignment surgeries. For children and adolescents with gender dysphoria they may
desire such interventions in order to establish an external appearance that more closely
aligns with their gender identity. The debate over how to treat children and adolescents

with GD is primarily an ethical dispute, one in which we must consider the guiding
ethical principles on which medicine and bioethics rely. Though implementing
appropriate interventions for gender dysphoria in the pediatric and adolescent
population is certainly paramount, the use of puberty suppression medications, and
cross-gender hormone therapy in this population is not ethically acceptable. Conclusive
and sufficient evidence of long term safety and evaluation of potential risks such as
adverse effects on metabolic and endocrine status, impaired increment of bone mass,
and interference with brain development has not met evidence based medicine
guidelines, and undermines basic ethical guiding principles.
1.2 Typical puberty development in youth
For a typically developing child, usually around age eleven in biological males
and ten in biological females the pituitary gland in the brain releases two hormonesluteinizing hormone and follicle stimulating hormone. When these hormones are
produced in higher concentrations they affect the sex glands in the testes (male) and
ovaries (female) producing sex hormones testosterone and estrogen respectively [20].
The production of these sex hormones cause the developmental stages in puberty.
These stages occur in a series of steps called Tanner Stages 1-5. The Tanner stages
present in varied ages depending on the individual, the scale defines physical
measurements of development based on external primary and secondary sex
characteristics; breasts, genitals, testicular volume and development of pubic hair. In
biological males, these stages enable an increase in testicular size, increasing
testosterone production, which enable increase pubic hair and phallic size [19]. A
typically developing male will grow axillary (armpit) hair and facial hair, and grow taller in
height and their voice changes. In biological females, estrogen production allows for
breast development, menstrual cycle will begin and females will experience growth of
pubic hair, and axillary hair [20].
1.3 Mechanism of puberty suppression medication
Puberty suppression is an agent which inhibits the the release of luteinizing
hormone and follicle stimulating hormones from the pituitary gland [7]. Inhibiting these
hormone prevents testosterone from being released from the testes, and estrogen from
being released from the ovaries. Without exposure to the sex hormones, estrogen and
testosterone, children and adolescents of pubertal age will not undergo the physical
changes associated with these hormones. Leuprolide or Depot Lupron is a common
suppression drug used. They can be injected intramuscularly and given on a monthly or
every 3-month basis. Supprelin or Histrelin is an implant version of puberty suppression
drug. This device is implanted under the skin and releases the agent over a period of
one year.
Puberty suppression medications are used for many different reasons. In some
children they have been approved by the Federal Drug Administration (FDA) for
treatment of precocious puberty [20], which is a premature onset of puberty. In this
case, puberty is only suppressed until a developmentally appropriate age for onset

occurs, then puberty is continued and occurs within typical limits. In adult populations,
puberty suppression medications are used for treatment of prostatic carcinoma in males
and may be used to treat endometriosis, uterine fibroids, or other female hormonerelated problems [7]. These treatment measures, have been extensively researched
and trialed for their corresponding population, as a sufficient treatment option to
manage otherwise detrimental health conditions [21]. Finally as stated previously,
puberty suppression medications are now increasingly used in order to suppress
endogenous sex hormone production in pediatric and adolescent populations with
gender dysphoria despite minimal longitudinal, clinical and evidence based research [1].
2. The case in favor of puberty suppression and similar medical interventions
In recent years, there has been an increase in referrals of gender-expansive and
transgender children to specialty pediatric centers which offer gender clinics, specific for
pediatric and adolescent populations with gender dysphoria or similar gender identity
disorders. It is not known whether this is because of increased prevalence or increased
recognition or acceptance of transgender communities, and other gender identity
related diagnoses. There are now forty gender clinics across the United States that
promote the use of pubertal suppression and cross-sex hormones in children and
adolescent populations [1]. The rationale for use of puberty suppression is to allow the
gender-dysphoric child time to explore gender identity free from the emotional distress
triggered by the onset of secondary sex characteristics that typically present in the
stages of puberty [8][6].
There is an adequate case in favor of utilizing puberty suppression, and cross
gender hormones in order to address the psychological, social, and emotional concerns
for children and adolescents faced with gender dysphoria. By suppressing the
individual’s production of sex hormones, administering cross hormone therapy for
transition to desired gender would be be more effective [6]. Puberty suppressive drugs
usage would effectively inhibit the endogenous pubertal changes that may worsen the
individual’s gender dysphoria, creating further emotional, social and psychological
distress [6]. In fact, those who support the use of such medication indicate that
withholding this treatment would be more harmful.
There is evident controversy surrounding suppression of puberty in children with
GD, however supporters have compiled minimum evidence in favor of this treatment
option. Medical, surgical and psychological interventions are considered to be
necessary components in the management of gender dysphoria in the adult population.
The goals of medical and surgical treatments are to align the patient’s physical
appearance to their internal gender identity. Medical treatment involves the
administration of cross-sex hormones, surgical interventions such as mastectomies,
salpingo-oophorectomies, hysterectomies, creating neophallus and orchiectomies with
the creation of a neovagina, which are permanent procedures [7]. In recent years, these
efforts have been extending into pediatric and adolescent populations. Adults, children
and adolescents alike may choose to undergo only medical treatment or also include
surgical interventions in order to function as their desired gender.

In the prepubertal population, there is an additional treatment possibility, the
suppression of puberty using continuous gonadotropin-releasing hormone (GnRH)
agonists. Those in favor of the utilization of this treatment say the fundamental benefit of
this strategy is that children gain time to reflect over their gender identity, without
becoming trapped in a body that is experienced as alien [8]. The importance of
preventing development of secondary sex characteristics during this period for those
who support its usage feel it is detrimental. Supporters claim if children are experiencing
considerable distress over their gender incongruence and proceed with natural pubertal
development then they are at higher risk for further psychological distress and may be
at risk for suicide, self-harm and similar behaviors [10]. Supporters claim that
suppressing puberty and allowing children the opportunity to explore their gender
identities decrease their risk for suicidal ideation and attempts.
Those who may proceed with a gender transition will have more success in
obtaining a more normal and satisfying appearance if puberty is arrested than if they
had waited until adulthood to transition [10]. This is because natural effects of puberty
such as matured height would be irreversible, or those effects that can be changed
(mature breast and mature genital development) would only be reversed through in
depth surgical procedures.
Further, youth experiencing gender dysphoria who received treatment via
puberty suppression have ample psychosocial outcomes, such as greater comfort with
their physical selves therefore resulting in fewer psychological complications. Should
youth on puberty suppressive medications decide not to change gender afterall, puberty
suppressant drugs can be withheld and development restarts as normal [2]. Supporters
profess that prepubescent children should be able to receive this treatment as long as
the clinician discusses all potential risks and benefits. Indicating that since puberty
suppression is the only therapy available for children with GD, those in favor for it’s
usage consider it unethical to deny this treatment option.
It is currently recommended that treatment be initiated when the patient is in the
Tanner II stage of puberty on the basis that during this stage a child has had some
experience of his/her biological gender and can therefore make a logical decision [2].
There is data that indicate that children who continue to experience gender dysphoria
into early adolescence will maintain a transgender identity, and delaying treatment may
cause further psychological effects [2]. Supporters stake their ethical argument on the
notion that if allowing puberty to progress appears likely to harm the child then puberty
should be suspended. Indicating that it would be unethical to allow a patient to suffer
through the distress of natural pubertal development when medicine can combat the
distress it causes.
3. The case against puberty suppression and similar medical interventions
As health care professionals, there is a moral obligation to alleviate suffering—
and for pediatric patients with GD, who are undoubtedly suffering, suppression of
puberty may present as a plausible possibility to manage this illness, however the
evidence based medicine to which medical interventions are founded upon is limited on

this subject, and therefore there is insufficient indication of this method being the safest
way to relieve suffering for these individuals.
Of course, it is worthwhile to note that exogenous continuous GnRH
administration is the standard of care for the treatment of precocious puberty, and for
this population its safety and efficacy has been extensively studied [20]. The
circumstances of utilizing GnRH in these populations and in those of young desiring to
delay or stop puberty all together, in some case well beyond natural pubertal timelines,
is distinguishable. Precocious puberty can be defined as sex hormone production or
exposure occurring earlier than the norms for specific gender and racial or ethnic
background. Identification of the child with pathological pubertal development allows for
accurate diagnosis and application of current treatment strategies, which include to use
of GnRHa treatment outlet such a implants, or injections [20]. Recent improvements in
therapeutic agents allow for complete suppression of precocious puberty with less
discomfort to the patient. Although approved for use by the FDA and pediatric
endocrinology associations, there are major gaps in understanding and in the area of
long-term outcomes, including endocrine and metabolic effects of precocious puberty
[20]. Deficits occur in lack of long-term data on the psychological and behavioral effects
of precocious puberty and the effects of GnRHa treatment. However, treatment in these
populations suppress puberty only until typical pubertal stages are expected, and in
many cases the child will go on to experience normal pubertal progression [20]. On the
contrary, children receiving suppression medications during puberty, which is the
recommended course of treatment for those with GD, do not typically go on to progress
into further stages of puberty. In a review of extensive literature, there is no evidence of
any large, randomized, controlled study that documents the alleged benefits and
potential harms to gender dysphoric children from pubertal suppression and decades of
cross-sex hormone use [22]. Further there seems to be no evidence of any long-term,
large, randomized, controlled study which compares the outcomes of various
psychotherapeutic interventions for childhood GD with those of pubertal suppression
followed by decades of synthetic steroids [22].In a modern society which attribute
pivotal medical successes on the basis of evidence-based medicine, this should give
health care practitioners, families, and the society at large a pause.
3.1 Evidence based medicine as an ethical implication
Evidence-based medicine is founded on the idea that decisions about the
care of individual patients should involve the “conscientious, explicit and judicious
use of current best evidence”[23]. Evidence based medicine is what guides to
improvements in knowledge and thereby benefiting the patient’s overall well being.
From an ethical perspective, the strongest arguments in support of evidence based
medicine are that it allows the best evaluated methods of healthcare as well as
potentially harmful methods to be identified and enables patients and doctors to
make better informed decisions. If a particular medical procedure or treatment has
sufficient evidence which would indicate in almost every circumstance, a positive
effect on the patient experiencing the treatment without causing physical, emotional
or psychological distress then after extensive clinical trials and further
recommendations by prestigious medical research organizations, a medical

procedure or treatment may be considered justified and beneficial. In the case
against the use of puberty suppression medication and similar treatments to
manage GD in youth, there is no such context to which evidence based practice can
be attributed. In a illustrative sense we might consider, a patient who has obvious
emotional and psychological distress that requests a medical treatment or procedure
which may, or may not relieve distress, the course of action which they are
requesting is purely experimental, do we implement this request to honor the
patient’s desires? This case would be further complicated if the patient was unable to
consent fully due to a lack of competence, or an immature neurological presentation.
In most circumstances, a provider would halt, ensuring more than adequate risk
versus benefit research and sound evidence based literature was evaluated prior to
proceeding with a course of action, granted it is ethically justified. It is dangerous and
ethically concerning to recommend or provide treatment which involves a minor
undergoing medical treatment without the existence of a pathophysiology, and for
such reasons it must be considered medical experimentation that does not justify the
risk to which youth are exposed. Gender dysphoria is currently the only circumstance
in which medical intervention does not cure a sick body, but healthy organs are
mutilated in the process of adapting physical and congruent psychological identity.
3.2 Risk of harm as an ethical implication
The claim that puberty-blocking treatments are fully reversible makes them
appear less drastic, but this claim is not supported by scientific evidence. As addressed
in previous sections, it remains unknown whether or not ordinary sex-typical puberty will
resume following the suppression of puberty in patients with gender dysphoria [9].
Additionally, there is evidence which suggests children receiving suppression
medications during puberty or prior to puberty do not typically go on to progress into
further stages of puberty, altogether disrupting or eliminating natural puberty and
replacing it with cross-hormonal therapy [9].
In a study of seventy pre-pubertal candidates that continued on to receive
puberty suppression it was documented that all subjects eventually embraced a
transgender identity and requested cross-sex hormones [11]. This statistic is alarming.
In typical cases of diagnosed GD eighty to ninety five percent of pre-pubertal youth do
not persist in their GD. Studies that show one hundred percent of pre-pubertal children
who received puberty suppression choose to later initiate treatment with cross-sex
hormones suggests that the use of such hormones may inevitably lead the individual to
identify as transgender, due to underlying mechanisms which occur within neurological
realms. The suppression of puberty prevents further endogenous masculinization or
feminization of the brain causing exposed children to be non-conforming. Current
recommendations involve the promotion of impersonation of an individual’s desired
gender while being treated with puberty suppression drugs, inevitably forcing already
confused children to take on the role of their non-biological sex [13]. These neurological
implications will prevent a youth from identifying as being the biological male or a
female they actually are, and could cause for further confusion or distress if they are
unable to accurately impersonate the opposite gender. A protocol of pubertal
suppression that sets into motion an inevitable outcome of transgender identification

that requires lifelong use of harmful synthetic hormones [12] is neither fully reversible
nor harmless.
It is also unclear whether children would be able to develop normal reproductive
functions if they were to withdraw from puberty suppression [12]. There is further
uncertainty on whether bone and muscle development will proceed normally for these
children if they resume puberty as their biological sex. There is additional cause for
concern when interfering with pubertal suppression at Tanner Stage 2, followed by the
use of cross-sex hormones which will leave these children sterile and without gonadal
tissue or gametes available for cryopreservation[12]. Sterilization of humans without
medically acceptable and sound justification, is ethically and morally wrong. When an
individual is sterilized, even as a secondary outcome of therapy, lacking full, free, and
informed consent, it is a violation of international law. The debate on pediatric consent
will not be discussed in great detail here, however it is of important ethical consideration
to note the implications of sterilizing a child without consent of their matured adult self
should be reason to evaluate alternative treatment options.
Other risks of pubertal suppression medications must be considered, and further
invalidate the use of these drugs for treatment of youth with gender dysphoria. The
GnRH agonists used for pubertal suppression in gender dysphoric children have been
discussed in previous sections in detail. In addition to preventing the development of
secondary sex characteristics, GnRH agonists have side effects which include arrest in
bone growth, decrease bone accretion, prevention of the sex-steroid dependent
organization and maturation of the youth brain, and as previously introduced, inhibit
fertility by preventing the development of gonadal tissue and mature gametes for the
duration of treatment. GnRH agonists prevent the maturation of gonadal tissue and
gametes in both sexes, the large percent of youth who desire to initiate treatment using
cross-sex hormones will be rendered infertile without any possibility of having genetic
offspring in the future because they will lack gonadal tissue and gametes [12]. If
guidelines were considered to delay use of puberty suppression medication until older
adolescence, or adolescents in later Tanner stages of pubertal development, this may
provide an opportunity for them to consider cryopreservation of gametes prior to
beginning cross-sex hormones. However this induces the burden and costly
interventions of using artificial reproductive technology in order to conceive genetic
offspring in the future, which may be especially gruesome in cases where adolescents
come to terms with their gender dysphoria after maturation of neurological brain
development in the mid-twenties [13]. There have been documented cases of
transgender adults who stopped their cross-sex hormones in order to allow their bodies
to produce gametes, conceive, and have a child, there is little guarantee that this is a
viable option in the long term [12].. Those individuals who undergo sex reassignment
surgery and have their reproductive organs removed are rendered permanently infertile
[12].
3.3 Risk of harm from cross-sex hormones as an ethical implication
Potential risks from cross-sex hormones to children with GD are based on the
adult literature. In adult literature there are potentially long-term safety risks associated

with hormone therapy, many findings have been deemed inconclusive [23]. Children
who transition will require these hormones for a significantly greater length of time than
their adult counterparts [7]. Due to this they may be more likely to experience
physiological morbidities than those researched in adults. Oral estrogen administration
to males put them at potential risk for experiencing: thrombosis/thromboembolism;
cardiovascular disease; weight gain; hypertriglyceridemia; elevated blood pressure;
decreased glucose tolerance; gallbladder disease; prolactinoma; and breast cancer
[15]. Females who receive testosterone may be at risk for low HDL and elevated
triglycerides; increased homocysteine levels; hepatotoxicity; polycythemia; increased
risk of sleep apnea; insulin resistance; and unknown effects on breast, endometrial and
ovarian tissues [15]. In addition gender altering surgeries offered after cross-hormone
completion carry its own set of irreversible risks.
3.4 Beneficence and non-maleficence for ethical consideration
It is imperative to note the ethical considerations of such risks involved when
determining the morality of administering these medication and treatment options to
children with gender dysphoria as a way to manage their psychological distress. While
it’s important to understand these efforts have been established in order to provide
solace, and improve the overall psychological status of affected children, we must
evaluate whether good intentions correlate to a greater overall good for these youth.
Ensuring youth with gender dysphoria receive adequate medical treatment and care is
undoubtedly the duty of medical professionals, however how we get to this is of
important discussion. In medical ethics, the term beneficence connotes acts of mercy,
kindness, and charity. It is understood even more broadly in ethical theory to include
effectively all forms of action intended to benefit or promote the good of other persons.
The ethical guiding principle of beneficence refers to a normative statement of a moral
obligation to act for the others' benefit, helping them to further their important and
legitimate interests, often by preventing or removing possible harms. While there is the
argument that inducing the evaluated medical treatments would in fact remove the harm
of potentially fatal outcomes from increased suicide risks, or remove the harm of further
psychological distress there isn’t enough evidence to support that proceeding with this
course of treatment is the best or safest way to get to the end result. Those in support of
this treatment, and those who oppose it have the same end result in mind, a positive,
more fulfilling life with little to no psychological distress. The difference lies in how this
goal is obtained and putting a youth at risk for many adverse side effects, when other,
evidence based practices such as psychological counseling and therapy have been
proven to be successful in alleviating distress is not ethically sound. In addition to a
moral obligation to beneficence, health care professionals have a moral obligation to
non-maleficence. By implementing a treatment with an increase in harmful risks that
could substantially harm the receiving patient we are not fulfilling our moral obligation to
do no harm and further do an injustice to our patient by neglecting to address the
underlying issues for psychological distress that is experienced in youth with gender
dysphoria.

3.5 Psychological implications for ethical consideration
Further psychological implications suggest there is a more beneficial treatment
for youth facing gender dysphoria that should be considered in place of initiating
pubertal suppression treatments and similar methods for care. There is certainly
evidence of a social contagion at play for those facing GD. For example, in many
communities, there are entire peer groups coming out or being diagnosed with gender
dysphoria and identifying as transgender at the same time [14]. Strong consideration
should be given to investigating a causal association between adverse childhood
events, including sexual abuse, and transgenderism, as addressed in previous sections
there is large body of literature documenting many potential causes for the onset of GD
[15]. It must be considered possible that some individuals develop GD and later claim a
transgender identity as a result of childhood maltreatment and/or sexual abuse. This is
an area in need of research, however if it is so then the same approach used similar
psychological contexts should be considered, such as intensive psychological therapy
and not the use of medical interventions like puberty suppression medications. The
American Psychiatric Association (APA), explains in the Diagnostic and Statistical
Manual of Mental Disorders (DSM-5) that GD is listed therein not due to the discrepancy
between the individual’s thoughts and physical reality, but due to the presence of
emotional distress that hampers social functioning [16]. The DSM-5 states a diagnosis
is needed in order for insurance companies to pay for the treatments of discussion
(puberty suppression medication) in order to alleviate the emotional distress of GD [16].
In the case of GD proceeding with medical interventions such as GRnH, and crosshormone therapy are not only emotionally distressing for the individuals but also lifethreatening. In this population those who desire surgery or additional extreme medical
interventions may very well be relieved of some emotional distress but these
procedures will do nothing to address the underlying psychological problem. With many
psychological disorders, if underlying issues are left unaddressed there is a risk that the
patient will develop worse conditions, or could potentially cause indirect harm by
increasing risk for suicide, depression and anxiety. According to the DSM-5, once
treatment with these medications or surgical intervention have been induced, and
distress is considered alleviated [16], then GD diagnosis is no longer applicable, thereby
disengaging funds for the patient to receive therapeutic intervention and potentially
posing a risk for further or worsened distress. If we aren’t cautious in this regard then
the art of psychotherapy will diminish as the field increasingly devolves into potentially
unnecessary medical interventions, with the risk of devastating results for patient
It has been standard practice for a physician or psychologist to help an
individual to align their thoughts with physical reality. In the case of gender dysphoria,
for an individual’s gender identity to align with biologic sex. Children with GD do not
have a disordered body, although they may feel as they do, it can be assumed in most
presentations their body is perfectly healthy. A child’s distress over developing
secondary sex characteristics does not mean that puberty should be treated as a
disease to be halted, but rather a phenomenon in need of further evaluation through
psychoanalysis. Up until recent years children presenting with GD were treated with the
approach of watchful waiting or pursuit of family and individual psychotherapy [16]. The

goal of therapy, was to address familial conflicts, treat any psychosocial morbidities in
the child, and aid the child in aligning gender identity with biological sex [16]. Experts on
both sides of the pubertal suppression debate agree that within this context, the majority
of children with GD accepted their biological sex by late adolescence (see previous
sections for statistics). The increase in utilizing pubertal suppression to treat GD is
promoted in order to avoid discrimination, violence, psychopathology, and suicide.
Which supporters claim are inevitable consequences if withholding of puberty blockers
or cross-sex hormones from a gender dysphoric child occurs. Yet, statistics revealing
that eighty to ninety five percent of gender-dysphoric youth emerge physically and
psychologically intact after passing through puberty without these interventions refute
this claim [1]. With evidence emphasizing the effectiveness of psychotherapy in youth
with GD [17], the cornerstone for suicide prevention or psychological distress prevention
should be the same for them as for all children facing psychological disorders. That is
with early identification and treatment of psychological comorbidities. If other treatment
options exist which provide decreased implications and are supported with in depth
analysis to be safe and effective in an attempt to preserve, honor and promote the good
for human life, then these treatment options must be the standard of care to conflicting
treatment options which could result in harm, maleficence and fail to honor the greater
good of the patient.
4. Conclusion
In closing the ethical considerations outlined and analyzed in this essay
involve illuminating an understanding of whether the administering pubertal suppression
with GnRH agonists, and cross-sex hormones to children with gender dysphoria are a
morally justified treatment to manage their psychological distress, or if safer more
understood alternatives exist. The importance of providing treatment options in this
population is essential in order to provide solace, and improve the overall psychological
status of affected children. The use of pubertal suppression drugs and cross-sex
hormones have been considered as a possible treatment option in order to achieve this
goal. However, it is crucial that health care professionals understand and consider that
good intentions do not indefinitely correlate to a greater overall good for these youth,
especially in the case of these interventions. Ensuring youth with gender dysphoria
receive adequate medical treatment and care is undoubtedly the duty of medical
professionals as indicated in this essay, however the use of inconclusive and under
researched methods [17] to manage gender dysphoria cannot be ethically justified and
therefore should be re-evaluated.
Providing potentially harmful and ultimately uncertain treatment to our future
generation should not be the standard care when there are treatment alternatives
available with empirical evidence supporting its effectiveness, such as psychotherapy.
Of course implementing appropriate interventions for gender dysphoria in the pediatric
and adolescent population is certainly needed, therefore we must continue to treat with
proven and safe methods while simultaneously researching more treatment options.
The use pubertal suppression with GnRH agonists, and cross-sex hormones in minors
may very well be an option in the future, but without more than sufficient and successful

long-term clinical trials [17], conclusive analysis on risk/benefits ratio, appropriate
initiation of safety protocols and FDA approval among other administrative
recommendations, these treatment methods cannot be utilized in an ethically
appropriate manner. Looking at future directions, appropriate longitudinal studies should
be performed, with consent and disclosure of the potential risks discussed previously, in
order to clarify safety concerns or lack thereof. Conclusive and sufficient evidence of
long term safety and evaluation must be performed in order to align with evidence
based medicine guidelines, and further considerations such as ensuring minimal harm
to the patient both in the present as well as in the future in order to uphold ethical
guiding principles which support the overall good for the patient of discussion. From an
ethical standpoint it is not morally justified to provide pubertal suppression medications,
and cross-sex hormones to minor populations until further evaluation of such methods
for treatment are performed instead, we should rely on evidence based and safer
methods for treatment such as psychotherapy.
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